|
|
一例金毛猎犬肝脏组织细胞肉瘤的多模态诊疗与长期生存分析
|
Abstract:
目的(Objective):探讨多模态诊疗策略对犬原发性肝脏组织细胞肉瘤(HHS)的诊疗价值及生存获益。方法(Methods):报告一例14岁雄性绝育金毛猎犬病例。通过体格检查、实验室检查(血常规、生化、CRP)、多模态影像学(X线、超声、超声造影CEUS、磁共振MRI)、细胞学及组织病理学确诊为原发性HHS。先行肿瘤细胞减灭术(减瘤率 > 85%),术后14天启动口服酪氨酸激酶抑制剂帕唑帕尼(3 mg/kg, Q24H)以抑制血管生成,术后第14天加用多柔比星化疗(30 mg/m2,Q3W,共5周期)。不良反应监测方案:化疗前/后48小时全血细胞计数(骨髓抑制);血压测量(Q2W);尿蛋白肌酐比(UPCR, Q4W);肝功能(ALT/ALKP, Q4W);心脏超声(每2周期)。结果(Results):患犬呈现食欲废绝、咳嗽、脓血性鼻涕及腹部肿块。实验室检查提示贫血、肝损伤及炎症。CEUS显示肝脏占位动脉期环状高增强,门脉期快速廓清(>40%/min,“快进快出”模式)。MRI显示T1WI稍低信号、T2WI/STIR中高信号、DWI高信号(弥散受限),动态增强呈“快进快出”。细胞学及组织病理学确诊为恶性组织细胞肉瘤。术后联合治疗耐受性良好,未出现严重高血压(收缩压 < 160 mmHg)、蛋白尿(UPCR < 0.5)或肝毒性。确诊后总生存期(OS)达456天。确诊后15个月并发鼻腔鳞状上皮癌,最终实施安乐死。结论(Conclusion):本例表明,手术减瘤联合多柔比星化疗及帕唑帕尼靶向治疗的多模式方案,可能显著延长犬HHS生存期(较文献报道多柔比星单药方案中位生存期(169天)提升268%)。多模态影像(CEUS, MRI)对HHS的术前诊断和评估具有重要价值。老年犬肿瘤管理中需警惕化疗相关继发癌变风险。
Objective: To evaluate the diagnostic value and survival benefits of a multimodal strategy for canine primary hepatic histiocytic sarcoma (HHS). Methods: A 14-year-old castrated male Golden Retriever was diagnosed with primary HHS via physical examination, laboratory tests (CBC, serum biochemistry, CRP), multimodal imaging (radiography, ultrasonography, contrast-enhanced ultrasonography [CEUS], magnetic resonance imaging [MRI]), cytology, and histopathology. The treatment protocol was designed based on cytoreductive enhancement theory: Cytoreductive surgery (>85% cytoreduction rate) was performed first, followed by oral pazopanib (tyrosine kinase inhibitor; 3 mg/kg, Q24H) initiated on postoperative day 14 to inhibit angiogenesis. Doxorubicin chemotherapy (30 mg/m2, Q3W, 5 cycles) commenced on postoperative day 14. Adverse event monitoring included: CBC 48 h pre/post-chemotherapy (myelosuppression); blood pressure Q2W; UPCR (urine protein-to-creatinine ratio) Q4W; hepatic enzymes (ALT/ALKP) Q4W; echocardiography every 2 cycles. Results: The dog presented with anorexia, cough, purulent/bloody nasal discharge, and an abdominal mass. Laboratory findings revealed anemia, hepatic injury, and inflammation. CEUS showed ring-like hyperenhancement in the arterial phase and rapid washout (>40%/min, “wash-in/wash-out” pattern) in the portal phase. MRI demonstrated: hypointense T1WI, hyperintense T2WI/STIR, restricted diffusion on DWI, and dynamic “wash-in/wash-out” enhancement. Cytology/histopathology confirmed malignant HS. The combined therapy was well-tolerated without significant
| [1] | Moore, P.F. (2014) A Review of Histiocytic Diseases of Dogs and Cats. Veterinary Pathology, 51, 167-184. https://doi.org/10.1177/0300985813510413 |
| [2] | Kennedy, K., Thomas, R. and Breen, M. (2016) Canine Histiocytic Malignancies—Challenges and Opportunities. Veterinary Sciences, 3, Article 2. https://doi.org/10.3390/vetsci3010002 |
| [3] | Affolter, V.K. and Moore, P.F. (2002) Localized and Disseminated Histiocytic Sarcoma of Dendritic Cell Origin in Dogs. Veterinary Pathology, 39, 74-83. https://doi.org/10.1354/vp.39-1-74 |
| [4] | Doka, R.M., Suter, S.E., Mastromauro, M.L., Bennett, A.L. and Hess, P.R. (2022) Doxorubicin for Treatment of Histiocytic Sarcoma in Dogs: 31 Cases (2003-2017). Journal of the American Veterinary Medical Association, 260, 1827-1833. https://doi.org/10.2460/javma.21.11.0498 |
| [5] | Latifi, M., Tuohy, J.L., Coutermarsh‐Ott, S.L., Klahn, S.L., Leeper, H. and Dervisis, N. (2020) Clinical Outcomes in Dogs with Localized Splenic Histiocytic Sarcoma Treated with Splenectomy with or without Adjuvant Chemotherapy. Journal of Veterinary Internal Medicine, 34, 2645-2650. https://doi.org/10.1111/jvim.15910 |
| [6] | Gomez, N.U., Rossi, F., Rademacher, N., et al. (2021) Contrast-Enhanced Ultrasound of Canine Hepatic Tumors. Veterinary Radiology & Ultrasound, 62, 298-306. |
| [7] | Owen, L.N. (1980) TNM Classification of Tumors in Domestic Animals. WHO. |
| [8] | Kato, Y., Murakami, M., Hoshino, Y., et al. (2020) MRI Characteristics of Canine Histiocytic Sarcoma. Journal of Veterinary Medical Science, 82, 589-595. |
| [9] | Lamb, C.R., Ciasca, T.C., Mantis, P., et al. (2016) MRI Features of Primary Hepatic Tumors in Dogs. Veterinary Radiology & Ultrasound, 57, 362-371. |
| [10] | Giori, L., Caleri, E., Faverzani, S., et al. (2021) Contrast-Enhanced Ultrasonography vs Magnetic Resonance for Focal Liver Lesions. Frontiers in Veterinary Science, 8, Article 689543. |
| [11] | Safai Zadeh, E., Dietrich, C.F., Dong, Y., et al. (2023) WFUMB CEUS Guidelines: Rare Malignant Mesenchymal Liver Lesions. Med Ultrasonogram, 25, 456-467. |
| [12] | London, C.A., Malpas, P.B., Wood-Follis, S.L., et al. (2012) Multi-Center, Placebo-Controlled, Double-Blind, Randomized Study of Oral Toceranib Phosphate for Recurrent Osteosarcoma. Veterinary and Comparative Oncology, 11, 306-315. |
| [13] | Marconato, L., Sabattini, S., Marisi, G., et al. (2023) Multi-Target Tyrosine Kinase Inhibitor in Canine Histiocytic Sarcoma. Veterinary and Comparative Oncology, 21, 123-131. |
| [14] | Fowles, J.S., Dawn, M. and Cicking, D. (2020) Doxorubicin Induces TP53 Mutations in Canine Cancers. Veterinary and Comparative Oncology, 18, 315-323. |
| [15] | Pang, L.Y. and Argyle, D.J. (2023) Telomere Shortening and DNA Damage in Aged Dogs with Cancer. The Veterinary Journal, 291, Article ID: 105919. |